MAPT and Alzheimer disease: Specific AD pathology biomarkers include 1) measurement of the beta-amyloid peptide and phosphorylated tau (phospho-tau) in the CSF and 2) positron emission computed tomography (PET) with amyloid peptide marker and PET with marker for tau protein.